Companies /Healthcare
Intellia Therapeutics Inc
NASDAQ: NTLA Biotechnology
$11.42
▲ $0.08 (+0.71%) today
Markets closed · 5:29pm ET

Intellia Therapeutics (NTLA) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+6.79%
Avg. EPS surprise
Consecutive EPS beats
NTLA vs Market · 30-day return after each reportNTLAS&P 500
−20%0%−34.5%−4.4%Q4 24+2.3%+6.7%Q1 25+3.7%+2.9%Q2 25−1.6%+2.5%Q3 25−18.4%−8.3%Q4 25−14.4%−0.2%Q1 26+13.4%−0.3%Q2 26
−20%0%Q4 24Q2 25Q4 25Q2 26
NTLA EPS Trend · estimate vs actualEstimateActual
$-1.20$-0.80$-0.40$0.00$-1.32$-1.27Q4 24$-1.27$-1.10Q1 25$-1.01$-0.98Q2 25$-0.98$-0.92Q3 25$-0.96$-0.83Q4 25$-0.90$-0.81Q1 26$-0.90$-0.80Q2 26
$-1.20$-0.80$-0.40$0.00Q4 24Q2 25Q4 25Q2 26
NTLA Revenue Trend · estimate vs actualEstimateActual
$0$7.0M$14.0M$21.0M$8.1M$12.9MQ4 24$12.0M$16.6MQ1 25$12.2M$14.2MQ2 25$14.1M$13.8MQ3 25$12.2M$23.0MQ4 25$13.8M$15.0MQ1 26$13.0M$7.7MQ2 26
$0$7.0M$14.0M$21.0MQ4 24Q2 25Q4 25Q2 26

How Often Does Intellia Therapeutics Beat Earnings Estimates?

Intellia Therapeutics beat EPS estimates in 7 of its last 7 reported quarters, and has beaten 7 quarters in a row.

NTLA quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 $-0.80 est. $-0.90 −1.95% $7.7M est. $13.0M −40.99%
Q1 2026 $-0.81 est. $-0.90 +9.81% $15.0M est. $13.8M +8.99%
Q4 2025 $-0.83 est. $-0.96 +13.71% $23.0M est. $12.2M +89.08%
Q3 2025 $-0.92 est. $-0.98 +6.49% $13.8M est. $14.1M −2.41%
Q2 2025 $-0.98 est. $-1.01 +2.51% $14.2M est. $12.2M +17.12%
Q1 2025 $-1.10 est. $-1.27 +13.46% $16.6M est. $12.0M +38.72%
Q4 2024 $-1.27 est. $-1.32 +3.52% $12.9M est. $8.1M +58.94%

Figures from SEC filings and company reports. Not investment advice.